Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

欣维可 - NMPA Drug Approval Details

Approvals/NMPA/Cross-linked Sodium Hyaluronate Injection

Approved

化学药品

Cross-linked Sodium Hyaluronate Injection

GENZYME CORPORATION🇨🇳 National Medical Products Administration

Approval Date: Jul 29, 2021
Approval ID: 8Dqlh2MlXf1
Company: GENZYME CORPORATION
Type: 化学药品

Approval Details

Approval Id: 8Dqlh2MlXf1
Approval Number: 国药准字HJ20160464
Generic Name: 交联玻璃酸钠注射液
Generic Name En: Cross-linked Sodium Hyaluronate Injection
Trade Name: 欣维可
Drug Type: 化学药品
Dosage Form: 注射剂
Strength: 2ml：玻璃酸钠16mg
Reg Date: 2021-07-29
Expired Date: 2026-07-28
Company Name: GENZYME CORPORATION
Production Company Name: GENZYME CORPORATION
Company Detail Path: /organization/genzyme-corporation
Production Company Detail Path: /organization/genzyme-corporation

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jul 29, 2021

Approval ID

8Dqlh2MlXf1

Type

化学药品

Back to NMPA Approvals